Sugi Predict

Sugi Predict / Compounds / SCHEMBL23623320

SCHEMBL23623320

SCHEMBL23623320

N#Cc1ccc(N2CCCC2)c(C(=O)NCc2cc(-c3cccs3)[nH]n2)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 4/20 0.40
▸ MEN1 O00255 3/20 0.40
▸ GPR6 P46095 3/20 0.40
▸ L3MBTL1 Q9Y468 1/20 0.40
▸ KDM5B Q9UGL1 1/20 0.39
▸ ALDH1A1 P00352 4/20 0.37
▸ KDM4E B2RXH2 2/20 0.37
▸ CSF1R P07333 2/20 0.37
▸ SMN1; SMN2 Q16637 3/20 0.36
▸ MAPT P10636 2/20 0.36
▸ USP2 O75604 1/20 0.36
▸ LMNA P02545 1/20 0.36
▸ MMP1 P03956 1/20 0.36
▸ SLC6A9 P48067 1/20 0.35
▸ NPC1 O15118 1/20 0.35
▸ GAA P10253 1/20 0.35
▸ NFKB1 P19838 1/20 0.35
▸ RAB9A P51151 1/20 0.35
▸ NFKB2 Q00653 1/20 0.35
▸ RELA Q04206 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23623317 0.90 LRRK2 (0.38) KMT2AMEN1GPR6L3MBTL1KDM5B
SCHEMBL23623339 0.86 ALDH1A1 (0.43) KMT2AMEN1L3MBTL1KDM5BALDH1A1
SCHEMBL23623306 0.86 KMT2A (0.46) KMT2AMEN1L3MBTL1KDM5BALDH1A1
SCHEMBL29930673 0.85 ALDH1A1 (0.42) KMT2AMEN1L3MBTL1KDM5BALDH1A1
SCHEMBL23611734 0.85 ALDH1A1 (0.42) KMT2AMEN1L3MBTL1KDM5BALDH1A1
SCHEMBL23623631 0.85 KMT2A (0.45) KMT2AMEN1L3MBTL1KDM5BALDH1A1
SCHEMBL23623240 0.85 KMT2A (0.45) KMT2AMEN1L3MBTL1KDM5BALDH1A1
SCHEMBL23623596 0.84 KDM4E (0.46) KMT2AMEN1L3MBTL1KDM5BALDH1A1
SCHEMBL23623302 0.79 FLT3 (0.48) KMT2AMEN1L3MBTL1KDM5BALDH1A1
SCHEMBL23623241 0.78 GAA (0.45) KMT2AMEN1L3MBTL1KDM5BALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023091590-A1 COMPOUNDS FOR USE IN TREATING GASTRIC CANCER BERG LLC (US) 2023-05-25 — — WO disclosed
US-20220002255-A1 UBE2K MODULATORS AND METHODS FOR THEIR USE THLIVERIS, ANDREW T. 2022-01-06 — — US disclosed
US-11091447-B2 UBE2K modulators and methods for their use BERG LLC (US) 2021-08-17 — — US disclosed
US-20210214320-A1 UBE2K MODULATORS AND METHODS FOR THEIR USE THLIVERIS, ANDREW T. 2021-07-15 — — US disclosed
WO-2021138540-A1 POLYCYCLIC AMIDES AS UBE2K MODULATORS FOR TREATING CANCER BERG LLC (US) 2021-07-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11091447-B2 UBE2K modulators and methods for their use UBE2N, UBE2B, UBE2E1 KMT2A 1523/4885MEN1 4260/4885GPR6 2355/4885
US-20220002255-A1 UBE2K MODULATORS AND METHODS FOR THEIR USE UBE2N, UBE2B, UBE2E1 KMT2A 1523/4885MEN1 4260/4885GPR6 2355/4885
US-20210214320-A1 UBE2K MODULATORS AND METHODS FOR THEIR USE UBE2N, UBE2B, UBE2E1 KMT2A 1523/4885MEN1 4260/4885GPR6 2355/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.